ApoGlyx has just closed a 6 million SEK investment round, coming from Almi Invest as well as from Swedish and Danish private investors.
This new capital will allow the company to progress its most advanced molecule to mandatory preclinical toxicology testing.
Furthermore, ApoGlyx has recently been accepted to Smile Incubator at Medicon Village in Lund. “Here, we will benefit from the input from experienced life science business development coaches, as well as have access to excellent laboratory facilities,” states the company in a press release.
Moreover, ApoGlyx was selected as one of four new members that will benefit from the Nordic Mentor Network for Entrepreneurship. NOME is an elite Nordic Mentoring Program for promising life science projects and startups, driven by the vision of transforming Nordic life science startups into internationally renowned commercial successes.
Photo of Michael Rutzler, CEO and co-founder, ApoGlyx